Comments Due Today on How Feds Should Rectify Drug Payment Cuts for 340B Hospitals

image of a calendar showing September 2022
Today is the deadline for public comments on Medicare’s proposed rule for how it will pay for hospital outpatient services and clinician-administered drugs in 2023.

Today is the deadline for public comments on Medicare’s proposed rule for how it will pay for hospital outpatient services and clinician-administered drugs in 2023.

340B stakeholders will be paying close attention to comments on how Medicare Part B should

Read More »

Health Policy Think Tank Commonwealth Fund Issues 340B Primer

pie chart of 340B covered entity purchases in 2021
The Commonwealth Fund has issued a primer that explores how 340B program growth has spawned controversy over the drug discount program.

The Commonwealth Fund, a well-respected think tank focused on promoting a high-performance and equitable healthcare system, published a primer on the 340B program last week, highlighting the program’s growth and the controversy its growth has sparked.    

“We did the report

Read More »

In Violation of ‘Spirit’ of Anti-Kickback Law, Drug Manufacturer Donations to Patient Assistance Charities Result in Bigger Profits, Study Finds

screenshot of Health Affairs article title
Drug manufacturers' donations to patient assistance charities effectively subsidize the purchase of their own drugs, a new study published in Health Affairs concludes. PhRMA counters that coupons and other forms of assistance help patients afford their out-of-pocket costs.

In a new study published in Health Affairs, researchers find that drug manufacturers are likely to profit from donations they make to patient assistance charities that help patients cover out-of-pocket costs associated with expensive treatments for serious and often rare

Read More »

Restoring 340B Hospitals’ Part B Drug Payments Would Cut Net Outpatient Payments for 80% of Hospitals, Private Cancer Doctor-Funded Study Finds

Outpatient exterior sign on hospital
80% of hospitals in Medicare’s outpatient prospective payment system would see their net payments decline next year if CMS ends a nearly 30% cut in 340B hospitals’ drug payments, according to a private oncologist group funded study.

Eighty percent of all hospitals in Medicare’s outpatient prospective payment system—including 52% of all 340B hospitals—would see their net OPPS payments decline next year if Medicare ends a nearly 30% cut in 340B hospitals’ drug payments that began in 2018,

Read More »

Senior HRSA Official Pedley to Deliver ASHP’s Prestigious William A. Zellmer Lecture Next Week

Rear Admiral Krista Pedley saluting
Rear Adm. Krista Pedley, director of HRSA's Office of Special Health Initiatives, addressed the 340B patient definition at a conference Tuesday.

U.S. Public Health Service Rear Adm. Krista Pedley, a top official at the Health Resources and Services Administration (HRSA) and former longtime head of the 340B drug pricing program, has been selected by the American Society of Health-System Pharmacists (ASHP)

Read More »
Industry Insights Logo

Maximizing 340B Program Value with Specialty Medication Access

Robin George headshot

SPONSORED CONTENT

At AllianceRx Walgreens Pharmacy, each covered entity we meet with describes circumstances unique to its hospital, patients, and pharmacy arrangements. The common element for all is the increasing complexity of 340B programming – often changing by the day. Other

Read More »

Judge Continues Stay in 340B Dispute Resolution Lawsuit

screenshot of HRSA 340B, Administrative dispute resolution web page
A federal district judge continued the stay in community health centers’ lawsuit over the 340B administrative dispute resolution process.

A federal district judge on Wednesday continued the stay in community health centers’ lawsuit against federal health officials over the administrative dispute resolution process for the 340B program after accepting the explanation for a missed deadline to file a report

Read More »

White House Seeks $27 Billion for COVID-19 and Monkeypox Response

bare arms presenting Monkeypox Mpox rash blisters
The Biden administration is requesting $27 billion to combat monkeypox and COVID-19, but Senate Republicans are signaling skepticism and resistance.

The Biden administration is requesting $27 billion to combat monkeypox and COVID-19 as part of a stopgap spending bill to fund the government past the end of fiscal year 2022, which ends Sept. 30. Senate Republicans are signaling skepticism and

Read More »

Federal Judge Asks About Overdue Status Report in 340B Dispute Resolution Case

Florence Pan headshot
U.S. District Judge Florence Pan signaled her displeasure with NACHC and the federal government for missing a Sept. 3 deadline for a legal filing.

A federal district judge in Washington, D.C., yesterday ordered community health centers to answer why she should not dismiss their lawsuit against federal health officials over the administrative dispute resolution process for the 340B program.

Judge Florence Pan of U.S.

Read More »

MedPAC May Back a Cut in Part B Drug Payments, This Time Not for 340B Hospitals Only

chart indicating average sale price of drugs MedPAC
MedPAC is considering whether to recommend reducing the 6% add-on to Part B drug reimbursement to decrease the incentives for providers to use higher-priced drugs.

Congressional Medicare advisers are weighing whether to recommend converting the 6% add-on to Part B drug reimbursement to a fixed fee capped at $175 for drugs that cost $15,000 or more, phased in starting with drugs costing above $700.

Medicare

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live